Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

LENSAR, Inc.'s ALLY Robotic Cataract Laser System has driven significant revenue and earnings growth. Read why LNSR stock is ...

A new economic paradigm points to the advantages of adding alternative investments to your portfolio for diversification and ...